UEG's content platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

LONG TERM PERSISTENCE OF USTEKINUMAB IN CROHN’S DISEASE: CLINICAL OUTCOMES AND PROGNOSTIC FACTORS

Georgios Kokkotis 1, Konstantina Chalakatevaki 1, Aikaterini Gaki 1, VASILIKI KITSOU 1, Nikolaos Kioulos 1, Michalis Gizis 1, Effrosyni Laoudi 1, Matina Lydia Chatzinikolaou 1, Ioannis Koutsounas 1, Giorgos Bamias 1

Affiliations

1 3rd Department of Internal Medicine, Sotiria Hospital, University of Athens, Athens, Greece

Summary

AI Generated

A retrospective cohort study of 99 Crohn's disease patients at a tertiary center found 70.1% maintained ustekinumab without corticosteroids at one year, declining to 45% at four years.

Among 99 patients (68.7% previously exposed to biologics, 35.4% with prior CD-related surgery), corticosteroid-free persistence on ustekinumab was 70.1% at one year, 59.2% at two years, and 45% at four years.
In multivariate analysis, lower Harvey-Bradshaw Index at ustekinumab initiation was the only factor independently associated with corticosteroid-free persistence at one year (OR=0.44, P=0.008).
Patients achieving corticosteroid-free persistence in the first year had significantly higher persistence at two and four years compared to those requiring corticosteroids (P<0.001).
Nine percent of patients required dose intensification and one percent required reinduction; no serious infections or malignancies were observed during follow-up.
This real-world experience may inform gastroenterologists managing moderate to severe Crohn's disease patients, particularly those with prior biologic exposure.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Ustekinumab is a monoclonal antibody that targets the p-40 subunit of the interleukins IL-12 and IL-23 and is used to treat moderate to severe Crohn's disease.

Aims & Methods

The present study aims to capture the experience of a tertiary center regarding the use of ustekinumab in patients with Crohn's disease in clinical practice [real-world] settings. This is a retrospective cohort study. Demographic and disease-related data on the day of ustekinumab initiation were collected. Study primary endpoint of the study was the persistence of treatment at the end of the first year without the administration of corticosteroids (cs-free). Secondary endpoints were the persistence of treatment at the end of the first, second and fourth year with and without the need for corticosteroids. The statistical program SPSS-23 was used for the analysis.

Results

In total, 99 patients have been registered until this point [women, 52.5%; mean age 42 years, SD=16; median disease duration=6 years IQR=1.5-11;A1/A2/A3, 6.1/65.7/28.3%; L1/L2/L3/L4, 58.6/7.1/34.3/12.1%; B1/B2/B3, 51.5/30.3/18.2%; perianal disease 26%]. Among study participants, 68.7% reported history of exposure to at least one biologic agent and 35.4% had undergone a CD-related surgery. At ustekinumab initiation 6.1% were receiving concomitant azathioprine, 4% methotrexate and 32.3%corticosteroids. 75.8% (75/99) continue ustekinumab with a median duration of administration of 14.5 months (range=0.5-66). Cs-free persistence in one-year was observed in 70.1% (54/77), cs-free persistence in two-years in 59.2% (29/49), and cs-free persistence in four-years in 45% (9/20). Simple persistence in one-, two- and four-years was observed in 84.4% (65/77), 61.2% (30/49) and 55% (11/20) respectively. Seven patients (9.3%) required intensification (90mg subcutaneously every 4 weeks) and one (1.3%) required reinduction (one-time weight-adjusted intravenous administration) due to loss of response. Patients that achieved cs-free persistence in one year were associated with higher persistence in two- and four-years compared with those who received corticosteroids during the first year of ustekinumab administration (P<0.001). Patients with a history of CD-related surgery achieved higher percentages of persistence (P<0.05). In univariate logistic regression, cs-free persistence in one-year was found to be associated with Harvey-Bradshaw Index [HBI] (OR=0.81, P=0.025), CRP [mg/L] (OR=0.96, P=0.059), history of CD-related surgery (OR=3.52, P=0.041), and neutrophils>5820/μL (OR=0.19, P=0.021). In multivariate logistic regression, cs-free persistence in one-year was found only to be negatively associated with HBI (OR=0.44, 95%CI: 0.24-0.81, P=0.008). No serious infection or malignancy has been observed.

Conclusion

Our analysis showed that patients with Crohn's disease achieved high rates of persistence on ustekinumab without the need of corticosteroids administration up to 4 years after the initiation of treatment. Patients with more severe diasease at drug initiation experienced lower persistence. Long-term administration of ustekinumab is not associated with any new safety concerns.

Disclosure

GB has acted as advisor/lecturer for Janssen, Pfizer, Takeda, Abbvie, MSD, Mylan, Genesis Pharma, Adacyte Therapeutics, Amgen, Ferring, Cooper; Funding (Grants/Honoraria): Pfizer, Takeda, Abbvie, Aenorasis; Research/Clinical Trials: Abbvie, Takeda. Genesis Pharma, Cooper.

Conference

UEG Week Copenhagen 2023

Topics

IBD

Submission format

Abstract

Session

PP 05 IBD (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

The new era of non-diet treatments in coeliac disease

Michael Schumann

THE ARTIFICIAL INTELLIGENCE IMPLEMENTATION IN THE TRAINING OF YOUNG ENDOSCOPISTS - DOES IT INFLUENCE THE QUALITY OF FUTURE COLONOSCOPIES?

Mirosław Szura

Presidential address

Matthias Löhr

A NOVEL DEEP LEARNING MODEL FOR PREDICTING COLORECTAL ANASTOMOTIC DEHISCENCE: A PIONEER MULTICENTER TRANSATLANTIC STUDY

Manuel Limbert

THE ROLE OF SIRTUIN 1 IN THE DEVELOPMENT AND PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE UNDER THE INFLUENCE OF STRESS FACTORS DURING THE WAR PERIOD

Tetyana Solomentseva

For the medical oncologist

Francesco Sclafani

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

The new era of non-diet treatments in coeliac disease

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

The new era of non-diet treatments in coeliac disease

Michael Schumann 1

Affiliations

1 Charité – Universitätsmedizin Berlin, Berlin, Germany

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

Postgraduate Teaching Programme Barcelona 2026

Topics

Paediatrics Small Intestine & Nutrition Primary Care Small Intestine & Nutrition

Session

PGT Opening: How to make and not miss the diagnosis - Coeliac disease across the spectrum

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

The new era of non-diet treatments in coeliac disease

Michael Schumann

THE ARTIFICIAL INTELLIGENCE IMPLEMENTATION IN THE TRAINING OF YOUNG ENDOSCOPISTS - DOES IT INFLUENCE THE QUALITY OF FUTURE COLONOSCOPIES?

Mirosław Szura

Presidential address

Matthias Löhr

A NOVEL DEEP LEARNING MODEL FOR PREDICTING COLORECTAL ANASTOMOTIC DEHISCENCE: A PIONEER MULTICENTER TRANSATLANTIC STUDY

Manuel Limbert

THE ROLE OF SIRTUIN 1 IN THE DEVELOPMENT AND PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE UNDER THE INFLUENCE OF STRESS FACTORS DURING THE WAR PERIOD

Tetyana Solomentseva

For the medical oncologist

Francesco Sclafani

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

THE ARTIFICIAL INTELLIGENCE IMPLEMENTATION IN THE TRAINING OF YOUNG ENDOSCOPISTS - DOES IT INFLUENCE THE QUALITY OF FUTURE COLONOSCOPIES?

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

THE ARTIFICIAL INTELLIGENCE IMPLEMENTATION IN THE TRAINING OF YOUNG ENDOSCOPISTS - DOES IT INFLUENCE THE QUALITY OF FUTURE COLONOSCOPIES?

Zofia Orzeszko 1, Tomasz Gach 1, Mirosław Szura 1

Affiliations

1 Jagiellonian University, Cracow, Poland

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Colonoscopy is a widely accepted screening test for detecting colorectal cancer. Computer-aided detection (CADe) based on artificial intelligence (AI) may be the way forward to improve its quality. As AI becomes a common upgrade in endoscopic equipment, an increasing number of young endoscopists are trained in an AI environment. However, how AI will impact trainees' future endoscopy outcomes remains unclear.

Aims & Methods

The study aimed to evaluate quality indicators in the first 1000 colonoscopies performed by newly trained endoscopists, comparing those trained in an AI environment to those trained in a non-AI environment. A study included 6,000 patients over 18 years old who underwent a colonoscopy for various reasons. The procedures were carried out by six young endoscopists, of which three were trained without AI and three with the assistance of the AI-powered Olympus Endo-Aid CADe system. The study retrospectively evaluated the first 1,000 procedures performed by each endoscopist after completing training. These procedures were performed without AI enhancement and relied entirely on the endoscopists' detection skills. Quality indicators were assessed in non-AI-training and AI-training groups. The morphology of detected polyps was assessed to determine the influence of AI during training on laterally spreading tumors (LST) detection.

Results

A total of 6,000 participants were included in the analysis. Withdrawal time (WT) was longer in the AI-training group (8 vs 9 min, p<0.05). Adenoma detection rate (ADR; 30.3 vs. 35.5%, p<0.05), advanced adenoma detection rate (AADR; 4.6 vs. 5.1%, p<0.05), and adenoma per colonoscopy score (APC; 0.73 vs. 0.75, p<0.05) were higher in the AI-training group. AI-assisted endoscopy training significantly improved LST-NG detection (p<0.05) for lesions smaller than 20mm.

	non-AI-training	AI-training	p-value
WT, min	8 (5-15)	9 (6-16)	<0.05
ADR, %	30.3	35.5	<0.05
AADR, %	4.6	5.1	<0.05
APC	0.73	0.75	<0.05

Conclusion

Implementing CADe during endoscopy training can positively impact quality indicators in the first 1,000 cases. After AI-enhanced training, the detection of LST-NG may improve. The potential of artificial intelligence in endoscopy training requires further investigation through prospective randomized controlled trials.

References

1. Kaminski MF et al. N Engl J Med. 2010 May 13;362(19):1795-803. doi: 10.1056/NEJMoa0907667. PMID: 20463339.
2. Repici A et al. Efficacy of Real-Time Computer-Aided Detection of Colorectal Neoplasia in a Randomized Trial. Gastroenterology. 2020 Aug;159(2):512-520.e7. doi: 10.1053/j.gastro.2020.04.062. Epub 2020 May 1. PMID: 32371116.
3. Vilmann AS et al. Computerized feedback during colonoscopy training leads to improved performance: a randomized trial. Gastrointest Endosc. 2018 Nov;88(5):869-876. doi: 10.1016/j.gie.2018.07.008. Epub 2018 Jul 19. PMID: 30031803.
4. Kaminski MF et al. Leadership training to improve adenoma detection rate in screening colonoscopy: a randomised trial. Gut. 2016 Apr;65(4):616-24. doi: 10.1136/gutjnl-2014-307503. Epub 2015 Feb 10. PMID: 25670810; PMCID: PMC4819605.
5. Forbes N et al. Association Between Endoscopist Annual Procedure Volume and Colonoscopy Quality: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2192-2208.e12. doi: 10.1016/j.cgh.2020.03.046. Epub 2020 Mar 30. PMID: 32240836.

Event

UEG Week Vienna 2024

Topics

Colorectal Endoscopy Histopathology

Submission format

Abstract

Session

AI for polyp detection: Advances, pitfalls and challenges

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

More Like This:

The new era of non-diet treatments in coeliac disease

Michael Schumann

THE ARTIFICIAL INTELLIGENCE IMPLEMENTATION IN THE TRAINING OF YOUNG ENDOSCOPISTS - DOES IT INFLUENCE THE QUALITY OF FUTURE COLONOSCOPIES?

Mirosław Szura

Presidential address

Matthias Löhr

A NOVEL DEEP LEARNING MODEL FOR PREDICTING COLORECTAL ANASTOMOTIC DEHISCENCE: A PIONEER MULTICENTER TRANSATLANTIC STUDY

Manuel Limbert

THE ROLE OF SIRTUIN 1 IN THE DEVELOPMENT AND PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE UNDER THE INFLUENCE OF STRESS FACTORS DURING THE WAR PERIOD

Tetyana Solomentseva

For the medical oncologist

Francesco Sclafani

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Presidential address

Matthias Löhr 1

Affiliations

1 Karolinska Institutet, Stockholm, Sweden

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Vienna 2024

Session

Opening Plenary

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

More Like This:

The new era of non-diet treatments in coeliac disease

Michael Schumann

THE ARTIFICIAL INTELLIGENCE IMPLEMENTATION IN THE TRAINING OF YOUNG ENDOSCOPISTS - DOES IT INFLUENCE THE QUALITY OF FUTURE COLONOSCOPIES?

Mirosław Szura

Presidential address

Matthias Löhr

A NOVEL DEEP LEARNING MODEL FOR PREDICTING COLORECTAL ANASTOMOTIC DEHISCENCE: A PIONEER MULTICENTER TRANSATLANTIC STUDY

Manuel Limbert

THE ROLE OF SIRTUIN 1 IN THE DEVELOPMENT AND PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE UNDER THE INFLUENCE OF STRESS FACTORS DURING THE WAR PERIOD

Tetyana Solomentseva

For the medical oncologist

Francesco Sclafani

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

A NOVEL DEEP LEARNING MODEL FOR PREDICTING COLORECTAL ANASTOMOTIC DEHISCENCE: A PIONEER MULTICENTER TRANSATLANTIC STUDY

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

A NOVEL DEEP LEARNING MODEL FOR PREDICTING COLORECTAL ANASTOMOTIC DEHISCENCE: A PIONEER MULTICENTER TRANSATLANTIC STUDY

Miguel Mascarenhas-Saraiva 1, Francisco Mendes 1, André Martins dos Santos 2, António Miguel Martins Pinto da Costa 3, Filipa Fonseca 4, Eduardo Carvalho 5, Nilza Ramião 5, Guilherme Barbosa 5, Maisa Vasconcellos 6, Abdullah Bunaiyan 7, Maria Almeida 1, Joana Mota 1, Tiago Ribeiro 1, Miguel Martins 1, João Afonso 1, Pedro Cardoso 1, Francisca Pinheiro 2, Matheus Carvalho 3, Marcos Eduardo Lera dos Santos 3, Eduardo De Moura 3, Marley Feitosa 6, Ahsan Javed 7, Guilherme Macedo 1, Manuel Limbert 4

Affiliations

1 Centro Hospitalar Universitário de São João, Porto, Portugal

2 Faculdade de Medicina da Universidade do Porto, Porto, Portugal

3 Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil

4 Instituto Português de Oncologia IPO, Lisboa, Portugal

5 INEGI – Institute of Science and Innovation in Mechanical and Industrial Engineering, Porto, Portugal

6 Hospital das Clínicas da Faculdade de Medicina de USP - Ribeirão Preto, São Paulo, Brazil

7 Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Colorectal anastomotic dehiscence (CAD) is one of the most severe postoperative complications in colorectal surgery, significantly impacting patient morbidity and mortality. Current risk assessment methods rely on clinical and intraoperative factors, but no real-time predictive tool exists. This study aimed to develop an artificial intelligence model based on intraoperative recording of the anastomosis for CAD prediction.

Aims & Methods

A convolutional neural network (CNN) was trained using a dataset of annotated frames from colorectal surgery videos across three international high-volume centers: IPO Lisboa, Hospital das Clínicas de Ribeirão Preto, São Paulo, Brazil and Royal Liverpool University Hospital. The dataset included a total of 5,356 annotated frames from 25 patients, 2,007 frames classified as CAD-positive and 3,349 as CAD-negative. Four CNN architectures (EfficientNetB0, EfficientNetB7, ResNet50, and MobileNetV2) were tested. Performance was evaluated using sensitivity, specificity, accuracy, and area under the receiver operating characteristic (AUROC) curve. Heatmaps were generated to identify key regions influencing predictions.

Results

The best-performing model achieved an accuracy of 99.55%, AUROC of 99.60%, sensitivity of 99.21%, specificity of 100%, PPV of 100%, and NPV of 98.94%. The model reliably identified CAD-positive frames and provided visual explanations through heatmaps.

Conclusion

To our knowledge, this is the first AI model developed to predict CAD using intraoperative video analysis. Its accuracy suggests the potential to redefine surgical decision-making by providing real-time risk assessment. Further refinement with a larger dataset and diverse surgical techniques could enable intraoperative interventions to prevent CAD before it occurs, marking a paradigm shift in colorectal surgery.

Event

UEG Week Berlin 2025

Topics

Colorectal Endoscopy Surgery

Submission format

Abstract

Session

Lower GI: Surgical considerations

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

The new era of non-diet treatments in coeliac disease

Michael Schumann

THE ARTIFICIAL INTELLIGENCE IMPLEMENTATION IN THE TRAINING OF YOUNG ENDOSCOPISTS - DOES IT INFLUENCE THE QUALITY OF FUTURE COLONOSCOPIES?

Mirosław Szura

Presidential address

Matthias Löhr

A NOVEL DEEP LEARNING MODEL FOR PREDICTING COLORECTAL ANASTOMOTIC DEHISCENCE: A PIONEER MULTICENTER TRANSATLANTIC STUDY

Manuel Limbert

THE ROLE OF SIRTUIN 1 IN THE DEVELOPMENT AND PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE UNDER THE INFLUENCE OF STRESS FACTORS DURING THE WAR PERIOD

Tetyana Solomentseva

For the medical oncologist

Francesco Sclafani

UEG Poster

Audio / Video Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

THE ROLE OF SIRTUIN 1 IN THE DEVELOPMENT AND PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE UNDER THE INFLUENCE OF STRESS FACTORS DURING THE WAR PERIOD

Yana Nikiforova 1, Galyna Fadieienko 1, Inna Kushnir 1, Oleksiy Gridnyev 1, Valentina Chernova 1, Tetyana Solomentseva 1

Affiliations

1 L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Sirtuin 1 (SIRT1) regulates mitochondrial function and biogenesis, carbohydrate and lipid metabolism, oxidative stress, inflammation, and apoptosis. All these factors play a role in the development and progression of non-alcoholic fatty liver disease (NAFLD).

Aims & Methods

The aim of the study was to investigate the role of SIRT1 in the development and progression of NAFLD under the influence of stress factors during wartime. The serum SIRT1 level was determined using an enzyme-linked immunosorbent assay (ELISA) with the "Human SIRT1 (Sirtuin 1) ELISA Kit." Visceral fat tissue (VFT) was measured using an OMRON BF-511 electronic device. Liver function tests, carbohydrate and lipid metabolism parameters, and C-reactive protein (CRP) levels were assessed using standard methods on an automatic biochemical analyzer "HumaStar 300SR." Statistical analysis was performed using the SPSS 17.0 statistical software package.

Results

A total of 88 NAFLD patients with metabolic disorders were examined, including 57 individuals (main group) who were exposed to war-related stress factors and 31 individuals (comparison group) examined in the pre-war period. It was found that SIRT1 levels were significantly higher in the main group, averaging 8.88 ± 0.23 ng/mL, compared to 4.75 ± 0.14 ng/mL in the comparison group (p < 0.05). Subgroup analysis showed a trend towards higher SIRT1 levels in normal-weight patients compared to those who were overweight or obese in the main group. A direct correlation was found between SIRT1 levels and VFT in both groups: r = 0.32 in the main group and r = 0.24 in the comparison group. Meanwhile, SIRT1 levels exhibited a weak negative correlation with abdominal obesity parameters (waist-to-hip ratio): r = -0.14 in the main group and r = -0.12 in the comparison group. A weak negative correlation was also observed between fasting glucose and insulin levels and SIRT1 (r = -0.17 and r = -0.24, respectively). However, an inverse correlation trend was demonstrated between SIRT1 and the HOMA index (r = -0.33). Correlation analysis results also indicated a weak negative relationship between SIRT1 levels and total cholesterol (r = -0.21) and a strong negative correlation between SIRT1 and triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) (r = -0.37). At the same time, a weak positive correlation was observed between SIRT1 and high-density lipoprotein cholesterol (HDL-C) (r = 0.11). When comparing CRP levels, hepatocyte cytolysis enzymes, and SIRT1, a weak inverse correlation was found with CRP and ALT levels (r = -0.17 and r = -0.22, respectively).

Conclusion

The results of our study provide evidence of the significant role of SIRT1 in regulating liver inflammation and the development and progression of NAFLD.

Disclosure

No conflict of interest

Conference

UEG Week Berlin 2025

Topics

Hepatobiliary

Submission format

Abstract

Session

LIVER (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

The new era of non-diet treatments in coeliac disease

Michael Schumann

THE ARTIFICIAL INTELLIGENCE IMPLEMENTATION IN THE TRAINING OF YOUNG ENDOSCOPISTS - DOES IT INFLUENCE THE QUALITY OF FUTURE COLONOSCOPIES?

Mirosław Szura

Presidential address

Matthias Löhr

A NOVEL DEEP LEARNING MODEL FOR PREDICTING COLORECTAL ANASTOMOTIC DEHISCENCE: A PIONEER MULTICENTER TRANSATLANTIC STUDY

Manuel Limbert

THE ROLE OF SIRTUIN 1 IN THE DEVELOPMENT AND PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE UNDER THE INFLUENCE OF STRESS FACTORS DURING THE WAR PERIOD

Tetyana Solomentseva

For the medical oncologist

Francesco Sclafani

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

For the medical oncologist

Francesco Sclafani 1

Affiliations

1 Université libre de Bruxelles, Bruxelles, Belgium

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Berlin 2025

Topics

Digestive Oncology Endoscopy Surgery

Session

Game changers in lower GI over the past decade: Neoplasm

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

The new era of non-diet treatments in coeliac disease

Michael Schumann

THE ARTIFICIAL INTELLIGENCE IMPLEMENTATION IN THE TRAINING OF YOUNG ENDOSCOPISTS - DOES IT INFLUENCE THE QUALITY OF FUTURE COLONOSCOPIES?

Mirosław Szura

Presidential address

Matthias Löhr

A NOVEL DEEP LEARNING MODEL FOR PREDICTING COLORECTAL ANASTOMOTIC DEHISCENCE: A PIONEER MULTICENTER TRANSATLANTIC STUDY

Manuel Limbert

THE ROLE OF SIRTUIN 1 IN THE DEVELOPMENT AND PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE UNDER THE INFLUENCE OF STRESS FACTORS DURING THE WAR PERIOD

Tetyana Solomentseva

For the medical oncologist

Francesco Sclafani